• 1
    Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, for the Tacrine Study Group. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 25232529.
  • 2
    Davis KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 12531259.
  • 3
    Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 12411245.
  • 4
    Summers WK, Tachiki KH, Kling A. Tacrine in the treatment of Alzheimer's disease. Eur Neurol 1989; 29: 2832.
  • 5
    Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985991.
  • 6
    Winker MA. Tacrine for Alzheimer's disease—which patient, what dose? JAMA 1994; 271: 10231024.
  • 7
    Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992998.
  • 8
    Hammel P, Larrey D, Bernuau J, et al. Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J Clin Gastroenterol 1990; 12: 329331.
  • 9
    Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Br Med J 1990; 300: 495499.
  • 10
    Woolf TF, Pool WF, Kukan M, Bezek S, Kunze K, Trager WF. Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: evidence for CYP1A2 involvement [Abstract]. ISSX Proceedings 1993.
  • 11
    Woolf TF, Pool WF, Bjorge S, Chang T, Goel OP, Trager WF. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Drug Metab Dispos Biol Fate Chem 1993; 21: 19.
  • 12
    deVries TM, O'Connor-Semmes RL, Koup JR, Forgue ST. Effect of cimetidine and low-dose quinidine on tacrine pharmacokinet-ics in humans. [Abstract]. Pharm Res 1993; 10: S377.
  • 13
    deVries TM, Siedlick P, Smithers JA. Effect of multiple-dose tacrine administration on single-dose pharmacokinetics in humans [Abstract]. Pharm Res 1993; 10: S333.
  • 14
    Madden S, Woolf TF, Pool WF, Park K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem Pharmacol 1993; 46: 1320.
  • 15
    Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolic activation of tacrine by human liver enzymes. Br J Clin Pharmacol 1994; 38: 1522.
  • 16
    Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1994; 6: 649656.
  • 17
    Park BK, Madden S, Spaldin V, Woolf TF, Pool WF. Tacrine transaminitis: potential mechanisms. Alzheimer Dis Assoc Dis-ord 1994; 8: S39S49.
  • 18
    Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363372.
  • 19
    Wietholtz H, Voegelin M, Arnaud MJ, Bircher J, Preisig R. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol 1981; 21: 5359.
  • 20
    Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503514.
  • 21
    Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, Josephs H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 261269.
  • 22
    Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83: 688697.
  • 23
    Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextro-methorphan metabolism: co-segregation of oxidative O-demeth-ylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38: 618624.
  • 24
    Park YH, Kullberg MP, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. J Pharm Sci 1984; 73: 2429.
  • 25
    Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacoge-netics 1994; 4: 171184.
  • 26
    Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414422.
  • 27
    Turgeon DK, Leichtman AB, Blake DS, Schmouder RL, Lown KS, Annesley TM, Watkins PB. The erythromycin breath test predicts inter and intra patient variation in OG 37–325 dosing requirements: A prospective study in renal transplant recipients. Transplantation 1994; 57: 17361741.
  • 28
    Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb MG, Merion RM, Watkins PB. P450 3A activity and cyclosporin A dosing in renal and cardiac transplant recipients. Clin Pharmacol Ther 1994; 56: 253260.
  • 29
    Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984; 517518.
  • 30
    Haughey DB, McNaney CA, Collis MS, Brown RR, Siedlik PH, Balogh L, Klockowki PM. Simultaneous determination of tacrine, 1-hydroxy-, 2-hydroxy-, and 4-hydroxy-tacrine in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1994; 83: 15821585.
  • 31
    Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, et al. Determination of CYP1A2 and NAT2 pheno-types in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116127.
  • 32
    Ford JM, Truman CA, Wilcock GK, Roberts CJ. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993; 53: 691695.
  • 33
    Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helg H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170180.
  • 34
    Sanz EJ, Villen T, Aim C, Bertilsson LS. S-mephenytoin hydroxylation phenotype in Swedish population—determined after administration with debrisoquin. Clin Pharmacol Ther 1989; 48: 496502.
  • 35
    Sinha R, Rothman N, Brown ED, Mark SD, Hoover RN, Lang NP, Kadlubar FF. Pan-fried meat containing high levels of het-erocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994; 54: 61546159.
  • 36
    Nousbaum JB, Berthou F, Carlhant D, Gouerou H, Riche C, Robaszkiewicz M. Four-week treatment with omeprazole increases the metabolism of caffeine. Am J Gastroenterol 1994; 89: 371375.
  • 37
    Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJ. Pharmacokinetics of tacrine hydrochloride in Alzhei-mers disease. Clin Pharmacol Ther 1989; 46: 634641.
  • 38
    Vermeulen NPE, Bessems JGM, Vandeseraat R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. Drug Metab Rev 1992; 24: 367406.
  • 39
    Watkins PB. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990; 10: 235250.
  • 40
    Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase mu genotype (GSTM1 0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39: 411415.
  • 41
    Forsyth DR, Morgan R, Truman CA, Ford JM, Wilcock GK, Roberts CJC. Pharmacokinetics of tacrine hydrochloride in patients with dementia. Proceedings of the BPS 1988; 19–21: 674675.
  • 42
    Cutler NR, Sedman AJ, Prior P, Underwood BA, Selen A, Gracon SI. Steady state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psychopharmacol Bull 1990; 26: 231234.
  • 43
    Cheng WSC, Murphy TL, Smith MT, Powell LW. Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47: 516524.
  • 44
    Eagger S, Levy R. Serum levels of tacrine in relation to clinical response in Alzheimer's disease. Int J Ger Psych 1992; 7: 115119.